2017 ACR/ARHP Annual Meeting

November 3-8, 2017. San Diego, CA.

View by Number View by Title View Sessions

View by Date

Abstract Number: 2084

Patients with Early Onset Gout Develop Earlier Severe Joint Involvement and Metabolic Comorbid Conditions
Abstract Number: 2085

Relationship between Gout and Asthma: A National Database Analysis
Abstract Number: 2086

Calcium Pyrophosphate Crystal Size, Shape and Appearance Variability
Abstract Number: 2087

Allelic Variants of ABCG2 and Gout Risk
Abstract Number: 2088

Clinical Significance of Urate Deposition in Tendon: A Dual-Energy CT Study
Abstract Number: 2089

Arhalofenate Acid Inhibits Urate Crystal-Induced Inflammatory Responses through Activation of AMP-Activated Protein Kinase (AMPK) Signaling
Abstract Number: 2090

Utility of Anakinra in Acute Crystalline Diseases: A Retrospective Study Comparing a University Hospital with Veterans Affairs Medical Center
Abstract Number: 2091

Initial Phase 2 Clinical Data of SEL-212 in Symptomatic Gout Patients: Monthly Dosing of a Pegylated Uricase (Pegsiticase) with Svp-Rapamycin Enables Sustained Reduction of Serum Uric Acid Levels By Mitigating Formation of Anti-Drug Antibodies
Abstract Number: 2092

Pilot Clinical Study of a Novel Unobtrusive Carpal Tunnel Tissue Manipulation Device in Reducing Symptoms of Carpal Tunnel Syndrome
Abstract Number: 2093

Comparison of Clinical and Laboratory Features of Patients with and without Allergic Conditions in IgG4-Related Disease: A Single-Center Experience in Japan
Abstract Number: 2094

Prevalence of Organ Involvement in Mixed Connective Tissue Disease
Abstract Number: 2095

Traditional Disease Modifying Anti-Rheumatic Drugs (tDMARDs), Hydroxychloroquine (HCQ) and/or Sulfasalazine (SSZ), Are Rapidly Effective in Immune Checkpoint Inhibitors-Induced Inflammatory Arthritis
Abstract Number: 2096

Nailfold Capillaroscopy Is an Opportunity for Telerheumatology
Abstract Number: 2097

Clinical Significance of KL-6 and SP-D As Serum Markers for Interstitial Lung Disease in Patients with Connective Tissue Disease
Abstract Number: 2098

Systemic Treatment for ACUTE Anterior Uveitis ( SYNTHETIC AND BIOLOGIC DISEASE-MODIFYINGANTIRHEUMATIC DRUGS) : A Systematic Literature Review

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].